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In order to establish themselves in distal sites, metastatic cancer cells need to acquire organ-
specific traits. Zhang et al. provide evidence in breast cancer that a tumor cell’s acquisition of prop-
erties for successful bonemetastasis is influenced by signals from the stroma of the primary tumor.Breast cancer commonly metastasizes to
bone in women with advanced disease to
cause bone destruction and associated
bone pain, fracture, hypercalcemia, and
paralysis due to spinal cord compression.
Themost devastating consequence is that
once breast cancer has spread to bone, it
is incurable. Breast cancersmediate bone
destruction by secreting factors that send
the normal bone-resorbing cell, the
osteoclast, into overdrive (Figure 1, osteo-
lytic phase) (Weilbaecher et al., 2011;
Roodman, 2004). Bone destruction then
releases growth factors stored in the
mineralized matrix, such as transforming
growth factor b (TGFb), that then increase
tumor production of osteolytic factors
and change tumor behavior to promote
growth in bone.
This feed-forward cycle in the bone
microenvironment has been the subject
of intense research that has produced
effective, but not curative, therapy for
this catastrophic complication. Current
therapy combines bone-targeted antios-
teoclast agents (such as bisphosphonate
zoledronic acid and RANK ligand inhibitor
denosumab) with antitumor therapy.
This standard of care improves skeletal
morbidity but does not cure disease
or have significant effects on survival.
Currently, there are no effective predic-
tors of who will develop bone metastases
to guide long-term preventive therapy. In
this issue ofCell, Zhang et al. (2013) impli-
cate the microenvironment of the primary
tumor as a determinant of bone metasta-
ses, at least in the case of triple-negative
(TN) breast cancer. Specifically, cancer-
associated fibroblasts (CAFs) in the
primary tumor can influence tumor cells
to develop the properties necessary tobecome successful bone metastases.
This new understanding provides amech-
anism that could lead to changes in the
prognostic, predictive, and preventative
management of women with advanced
breast cancer and bone metastases.
The extensive study reveals an associa-
tion of breast cancer bone metastasis
with a gene expression signature (Src
response signature, SRS) that denotes
activation of Src and Src-dependent
enhancement of PI3K-Akt signaling to
CXCL12 and IGF1, particularly in TN
breast cancers. TN breast cancer lacks
expression of the estrogen receptor (ER),
progesterone receptor, and HER2 and
comprises about 15% of primary breast
cancers but is overrepresented in patients
with metastatic disease (Anders et al.,
2013). It is particularly aggressive, and
unlike hormone-receptor-positive breast
cancer, which often metastasizes to
bone, TN breast cancer frequently metas-
tasizes to nonbone sites. The present
study focuses on a subset of TN breast
cancer that metastasizes to bone and is
characterized by a high level of Src activ-
ity and a high sensitivity to PI3K-Akt
pathway activation by CXCL12 and IGF1
(Zhang et al., 2009).
Currently, the use of chemotherapy and
radiation does not differ significantly
between early-stage TN and non-TN
breast cancer (Anders et al., 2013), but
findings presented here, if born out in clin-
ical trials, could shift that view. Indeed,
SRS+ status is a strong predictor of
bone metastases in TN breast cancer
(Zhang et al., 2009). Given that Src activa-
tion does not confer a growth advantage
in primary breast cancer and that it is
not mutated or amplified in breast cancer,Cell 15the authors looked for mechanisms that
lead to accumulation of Src-hyperactive
cells in primary breast cancer. What they
find in TN breast cancer is a stroma-
driven selection for breast cancer clones
that are primed for bone metastases, a
process governed by CXCL12 and IGF1
from mesenchymal stromal cells that se-
lects for Src-hyperactive cancer cell
clones that thrive in environments con-
taining these signals (such as bone).
The authors examined primary human
breast cancer and show that most ER+
and half of the HER2+ tumors have
SRS+ signatures. SRS+ status is further
shown to be a common downstream indi-
cator of multiple mutations in PIK3CA in
TN tumors. Then, by comparing SRS
and SRS+ TN tumors in independent clin-
ical data sets (and focusing on genes that
are enriched in SRS+ tumors but are not
part of the SRS gene set itself), the
authors reveal that CXCL12 and IGF1,
among others, are also overexpressed in
bone metastases tissues compared to
other sites. Intriguingly, these cytokines
are present in the bone marrow microen-
vironment where the tumors preferentially
metastasize.
The source of these cytokines in the
primary tumor is cancer associated
(CAFs), and CAF content is associated
with the propensity of TN tumors to
metastasize to bone. Thus, the authors
propose a ‘‘metastasis seed preselec-
tion’’ hypothesis and show that the select-
able trait, Src hyperactivity, is present in
the cancer cells where it is heteroge-
neously distributed. They use restrictive
growth conditions to produce MDA-MB-
231 breast cancer clones that grow in
the presence of CXCL12 and IGF1. These4, August 29, 2013 ª2013 Elsevier Inc. 957
Figure 1. Bone Metastases in Breast Cancer
TN breast cancer lacks expression of the ER, progesterone receptor, and
HER2. TN primary tumors with abundant CAFs select for primary tumor cells
with enhanced Src activity (SRS) by secretion of CXCL12 and IGF1, which
mimics what bonemarrow stromal cells do in the bonemicroenvironment. This
gives the tumor cells enhanced ability to survive via Akt signaling and to
become established in the bone microenvironment in a ‘‘preosteolytic’’ stage.
Eventually, bone metastases become osteolytic and interact with the bone
microenvironment to stimulate osteoclast activity via factors such as PTHrP,
IL-11, and VEGF. The mechanism for the switch from ‘‘preosteolytic’’ to
‘‘osteolytic’’ stage is unclear and requires further investigation. Bone-derived
factors, such as TGF-b, may be responsible by acting on the tumors to
produce osteolytic factors and fuel a feed-forward cycle in the bone, which
ultimately results in bone destruction.clones (MDA231-CI) have Src
hyperactivity that is not acti-
vated by CXCL12 or IGF1,
but rather, these cytokines
enhance the activation of the
PI3K-Akt pathway, an effect
that is blocked by the Src
kinase inhibitor dasatinib.
In vivo MDA231-CI causes
more bone metastases when
inoculated into the left cardiac
ventricle or into the mammary
fat pad. The latter is remark-
able, as spontaneous bone
metastases rarely occur from
primary (mammary fat pad)
breast tumors in mice.
In these in vivo studies,
bone lesions formed by
MDA231-CI are restricted to
the bone marrow cavity and
are not associated with in-
creased osteoclast activity or
bone destruction, compared
with lesions from the aggres-
sive bone metastatic MDA-
MB-231 clone, MDA231-
BoM1833 (Kang et al., 2003),
which exhibits massive bone
destruction and osteoclast
hyperactivity. Further, the
MDA231-CI clones do not ex-
press the genes associated
with bone metastases (Kang
et al., 2003), indicating that
MDA231-CI clones spontane-
ously present a survival andgrowth advantage in the bone marrow,
prior to the onset of the osteolytic stage.
Collectively, these elegant findings
raise a number of questions. First, are
these findings relevant in different breast
cancers or other types of cancer? Next,
CAFs make the primary tumor more like
the bone site by producing CXCL12 and
IGF1, which confers survival and growth
advantage to establish at the bone site.
However, in the present study, tumors at
this ‘‘preosteolytic’’ stage do not produce
osteolytic factors, stimulate osteoclast
activity, or destroy bone. This raises the
question of whether, in the MDA231-CI
model, the tumors progress to an ‘‘osteo-
lytic phase’’ as we observe in women with
advanced breast cancer and bonemetas-
tases? If so, what mediates progression
to the osteolytic phase? One possibility
is the bone microenvironment; mineral-958 Cell 154, August 29, 2013 ª2013 Elsevieized bone matrix is a rich storehouse of
growth factors such as TGFb and IGF1
and 2 that can induce tumor expression
of osteolytic factors such as PTHrP and
IL-11 (Yin et al., 1999; Kang et al., 2003)
(Figure 1). What is the clinical relevance
of the preosteolytic phase or the clinical
evidence that this entity exists in women
with TN breast cancer? Could a preosteo-
lytic phase be detected by activity on PET
scan without evidence of bone destruc-
tion? Will therapy directed against Src or
the PI3K-Akt cell survival pathway be
effective if the tumor is already in the os-
teolytic phase? Certainly, preclinical and
small clinical trials show that Src inhibitors
have antiosteoclast as well as antitumor
activity in the setting of established bone
metastases (Myoui et al., 2003; Rucci
et al., 2006; Campone et al., 2012), but
the present study indicates that suchr Inc.therapy should start in the
preosteolytic phase. Will
combination therapy directed
against Src or PI3K-Akt as
well as osteoclast activity
(such as bisphosphonates or
RANK ligand inhibitors) be
more effective in patients
with established clinical bone
metastases and evidence of
bone destruction than either
alone? What about using
antiosteoclast therapy with
bisphophonates or RANK
ligand inhibitors to prevent
bone metastases? Would
such a preventive approach
be too late? Do we need
to prevent the preosteolytic
stage in order to prevent
bone metastases? The an-
swers to these questions will
likely be answered by ongoing
clinical trials as well as future
clinical trials and observations
based on this work.
Although the percentage of
patients with bone-metastatic
TN breast cancer is small,
showing that the primary
tumor stroma mediates a
bone metastasis phenotype
addresses the global concept
of how organ-specific meta-
static traits may arise. Obvi-
ously, the findings need to
be confirmed in clinical trialsas well as in other breast cancer types
and different tumors. Regardless, any
real estate broker will tell you that it is
location, location, location and the neigh-
borhood that determines the ultimate
worth of a given home. Likewise, the
neighborhood, or microenvironment, of a
tumor cell can determine its ultimate des-
tiny. In the case of the tumor cell, the pri-
mary tumor microenvironment may have
as much influence on tumor behavior as
that at the final metastatic destination.
The conclusion is simple: the microenvi-
ronment matters. More importantly, it
may dictate therapy. The findings pre-
sented here could change the general
principles guiding the therapy of early-
stage TN breast cancer and differentiate
it from treatment of early-stage non-TN
breast cancer. If clinical trials confirm
the present findings, TN breast cancer
patients with fibroblast-rich stroma in the
primary tumor or with bone metastasis
may benefit from therapies that target
the PI3K-Akt cell survival pathway or its
amplifier Src to prevent or treat bone
metastases. Until such questions are
addressed by prospective clinical trials,
we will continue management of bone
metastases with the combination of
bone-targeted therapy as well as dis-
ease-specific therapy but will be opti-
mistic that insight into the primary as
well as the metastatic microenvironment
will have profound implications to guide
our future therapy.
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Proper chromosome segregation depends on correct attachments between microtubules and
kinetochores. Budding yeast have been thought to achieve these attachments with different
kinetics than other eukaryotes. Now, deploying specialized data processing techniques to achieve
super-resolution images, Marco et al. demonstrate that this tractable cell-cycle model system
shares more similarities with plants and animals than previously thought.Dividing eukaryotic cells face a universal
challenge—in order to deliver duplicated
chromosomes to separate daughter cells,
they must establish stable connections
between a pair of sister kinetochores
residing on each mitotic chromosome
and microtubules of the mitotic spindle.
This process, known as chromosome
biorientation, involves molecular mach-
ines and regulatory feedback circuits
that are conserved throughout all simple
and complex eukaryotes. Malformed at-
tachments, such as when a pair of kineto-
chores attach to the same pole (‘‘syntelic’’attachments), cannot properly segregate,
and result in aneuploidy, are linked to birth
defects and cancer promotion in animals
and humans. Several model systems are
used to study mitosis, with S. cerevisiae
being one of the most powerful and pop-
ular. Unlike most animal and plant cells,
this budding yeast uses a closed mitosis
where the nuclear envelope remains
intact throughout M phase. The spindle
pole body (SPB) is embedded in the nu-
clear envelope and nucleates intranuclear
microtubules that attach to kinetochores
throughout the cell cycle. A prevailingview has been that biorientation occurs
early in budding yeast, before M phase,
as opposed to biorientation in animal
and plant cells that occurs gradually
throughout M phase in an apparently
random cycle of microtubule-kinetochore
destabilization and reattachment. In this
issue of Cell, Marco et al. (2013) revisit
this issue by directly imaging yeast
kinetochores during chromosome bio-
rientation. They are by no means the first
to make such a measurement, but their
approach is the most comprehensive
and direct to date, and their results clarify4, August 29, 2013 ª2013 Elsevier Inc. 959
